Hero

News & Events

Mestag in the News
BioCentury Article: Mestag: Attacking Tumors from Within

Fierce Biotech: Merck & Co. signs $1.9B deal with Mestag to explore fibroblast therapies for inflammation

Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial

Mestag Therapeutics Selected to Present Targeted LTBR Agonist MST‑0312 in Late‑Breaking Session at AACR Annual Meeting

Mestag Therapeutics Announces $40 Million Financing and Appoints Chief Medical Officer and Chief Development Officer in Preparation to Enter the Clinic

Mestag Therapeutics to Present Data on Targeted LTBR Agonist MST-0312 at Cancer Immunotherapy Keystone Symposia

Mestag Therapeutics Appoints Dr. Matthew Sleeman as Chief Scientific Officer

View All Press Releases

Keystone Symposia on Cancer Immunotherapy – Québec, Canada

March 15-18, 2026

Conference Website

BioEquity Europe – Prague

Conference Website